abrdn Life Sciences Investors (NYSE:HQL) Sets New 52-Week High – Time to Buy?

abrdn Life Sciences Investors (NYSE:HQL) reached a new 52-week high during trading on Monday . The company traded as high as $18.48 and last traded at $18.2210, with a volume of 49296 shares trading hands. The stock had previously closed at $17.96.

abrdn Life Sciences Investors Price Performance

The business has a 50-day simple moving average of $17.53 and a two-hundred day simple moving average of $17.06.

abrdn Life Sciences Investors Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st will be paid a $0.56 dividend. This represents a $2.24 dividend on an annualized basis and a dividend yield of 12.2%. The ex-dividend date of this dividend is Thursday, May 21st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. LPL Financial LLC raised its position in abrdn Life Sciences Investors by 20.0% in the fourth quarter. LPL Financial LLC now owns 448,846 shares of the company’s stock worth $7,532,000 after acquiring an additional 74,787 shares in the last quarter. Raymond James Financial Inc. boosted its position in shares of abrdn Life Sciences Investors by 12.5% during the 3rd quarter. Raymond James Financial Inc. now owns 423,031 shares of the company’s stock valued at $6,561,000 after purchasing an additional 47,071 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in shares of abrdn Life Sciences Investors by 1.8% in the 4th quarter. Flagship Harbor Advisors LLC now owns 363,381 shares of the company’s stock worth $6,098,000 after purchasing an additional 6,257 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of abrdn Life Sciences Investors by 57.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock worth $5,898,000 after purchasing an additional 132,098 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of abrdn Life Sciences Investors by 24.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 209,681 shares of the company’s stock worth $3,254,000 after purchasing an additional 41,255 shares in the last quarter. Institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.